Chemotherapy of lung, GU and primary unknown cancer
MD with Distinction University of Saskatchewan
- Ho C, Bebb G, Murray N. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J Clin Oncol 24: 3212-3213, 2006.
- Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi K. First and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone refractory prostate cancer: does sequence matter? Cancer 106:1041-6, 2006.
- Murray N, Turrisi, A. A review of first-line treatment for small cell lung cancer. J Thorac Oncol 1: 270-278, 2006.
- Nemunaitis J, Murray N. Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol 1:756-761, 2006.
- Laurie S, Ding K, Whitehead M, Feld R, Murray N, Shepherd F, Seymour L. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Annals of Oncology 18: 1051-1055, 2007.
- Pugh, T, Bebb G, Barclay L, Ho, C, Murray N, Melosky B, Laskin J, Marra M. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer 7: 1471, 2007.
- Erridge S, Murray B, Williams L, Brewster D, Price A, Murray N, Sheehan F. Improved survival from lung cancer in British Columbia compared to Scotland – are different treatment rates the whole story? Lung Cancer 2008 (in press).
- Heng D, Chi K, Murray N, Jin T, Garcia J, Bukowski R, Kollmansberger C. A Population-based study evaluating the impact of sunitinib evaluating overall survival in the treatment of patients with metastatic renal cell carcinoma. Cancer 2008 (in press).
- Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld R, Murray N, Shepherd F. Malignant mesothelioma: Canadian perspective and research directions. Current Oncology 15; 62-69, 2008.
- Lee C, Murray N, Anderson H, Rao S, Bishop W. Outcomes with platinum-based combination chemotherapy for treatment of malignant mesothelioma: A review of practice in British Columbia. Lung Cancer 53; 353-361, 2008.
- Murray N, Klasa R. Reconsideration of the American Society of Clinical Oncology/ American Society of Hematology Erythropoiesis Stimulating Agent Guidelines. J Clin Oncol 26; 3096-3097, 2008 (letter).
- Murray N. The Quest for an efficacious lung cancer vaccine. Clin Lung Cancer 9; S4-5, 2008 (editorial).
- Butts C, Murray N, Smith C, Ellis P, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Souliers D. A multicentre open-label study to assess the safety of a new foumulation of BLP25 liposome vaccine in patients with unresectable stage III non-small cell lung cancer. Clinical Lung Cancer 11; 391-395, 2010.
- Dong X, Guan J, English J, Flint J, Yee J, Evans K, Murray N, MacAulay C, Ng R, Gout P, Lam W, Laskin J, Ling V, Lam S Wang Y. Patient-Derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16;1442-51, 2010.
- Kollmannsberger C, Daneshmand S, So A, Chi K, Murray N, Moore C, Hayes-Lattin B, Nichols C. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol 28:537-542, 2010.
- Kollmannsberger C, Tyldesley S, Moore C, Chi K, Murray N, Daneshmand S, Black P, Duncan G, Hayes-Lattin B, Nichols C. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2010.
- Michels J, Ellard S, Le L, Kollmannsberger C, Murray N, Tomlinson E, Carr R, Chi K. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Annals of Oncology 21:305-11, 2010.
- Palma D, Tyldesley S, Sheehan F, Mohamed I, Smith S, Wai E, Murray N, Senan S. Stage I Non-small Cell Lung Cancer in patients aged 75 years and older. Journal of Thoracic Oncology 5, 1-7, 2010.
- Butts C, Maksymiuk A, Goss G, Souliers D, Marshall D, Cormier Y, Ellis P, Price A, Sawhney R, Beier F, Falk M, Murray N. Updated survival analysis in patients with stage IIIB or IV non-small cell lung cancer receiving BLP 25 limposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137; 1337-42, 2011.
- Laurie SA, Gupta A, Chu Q, Lee CW, Morzycki W, Feld R, Foo AH, Seely J, Goffin JR, Laberge F, Murray N, Rao S, Nicholas G, Laskin J, Reiman T, Sauciuc D, Seymour L. A phase II study of sunitinib in malignant pleural mesothelioma: the NCIC Clinical Trials Group. Journal of Thoracic Oncology 11: 1950-1954, 2011.